PriceTargets.com logo

CSL - CSLLY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$81.94 As of 09/21/2023 01:00 AM ET
▼ -2.95 (-3.48%)

This chart shows the closing price for CSLLY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CSL Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSLLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSLLY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for CSL in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $81.94.

This chart shows the closing price for CSLLY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in CSL. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/10/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform
9/23/2022Jefferies Financial GroupUpgradeHold ➝ Buy
10/5/2021Jefferies Financial GroupUpgradeHold ➝ Buy
8/18/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
6/24/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
6/23/2021CitigroupDowngradeBuy ➝ Neutral
6/16/2021MacquarieDowngradeOutperform ➝ Neutral
5/4/2021MacquarieUpgradeNeutral ➝ Outperform
3/23/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
3/10/2021CitigroupUpgradeNeutral ➝ Buy
2/18/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral
1/27/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
1/21/2021CitigroupUpgradeNeutral ➝ Buy
11/11/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
8/20/2020CitigroupDowngradeBuy ➝ Neutral
5/28/2020CitigroupUpgradeNeutral ➝ Buy
4/14/2020CitigroupDowngradeBuy ➝ Neutral
4/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
3/13/2020Jefferies Financial GroupUpgradeHold ➝ Buy
3/13/2020CitigroupUpgradeNeutral ➝ Buy
2/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
1/23/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
12/4/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
10/21/2019Jefferies Financial GroupInitiated CoverageBuy
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2023
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2023
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2023
  • 3 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
CSL logo
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Read More

Today's Range

Now: $81.94
Low: $81.94
High: $82.34

50 Day Range

MA: $87.00
Low: $81.94
High: $91.08

52 Week Range

Now: $81.94
Low: $81.94
High: $110.25

Volume

36,822 shs

Average Volume

83,687 shs

Market Capitalization

$79.16 billion

P/E Ratio

N/A

Dividend Yield

1.39%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of CSL?

The following sell-side analysts have issued stock ratings on CSL in the last twelve months: Credit Suisse Group AG, and Jefferies Financial Group Inc..
View the latest analyst ratings for CSLLY.

What is the current price target for CSL?

0 Wall Street analysts have set twelve-month price targets for CSL in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CSL in the next year.
View the latest price targets for CSLLY.

What is the current consensus analyst rating for CSL?

CSL currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CSLLY will outperform the market and that investors should add to their positions of CSL.
View the latest ratings for CSLLY.

What other companies compete with CSL?

Other companies that are similar to CSL include Zoetis, GSK, Regeneron Pharmaceuticals, Takeda Pharmaceutical and Bristol-Myers Squibb. Learn More about companies similar to CSL.

How do I contact CSL's investor relations team?

CSL's physical mailing address is 45 Poplar Road, Parkville C3, 3052. The company's listed phone number is (139) 389-1911 and its investor relations email address is [email protected]. The official website for CSL is www.csl.com.au. Learn More about contacing CSL investor relations.